Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
Public ClinicalTrials.gov record NCT01406548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens. This information will permit a comparison of the possible risks and benefits of different dosing regimens of the study drug to enable optimal doses and dose intervals to be tested in subsequent studies.
Study identification
- NCT ID
- NCT01406548
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 85 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2011
- Primary completion
- Sep 30, 2013
- Completion
- Sep 30, 2013
- Last update posted
- Sep 14, 2022
2011 – 2013
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Anaheim | California | 92801-2811 | — |
| Novartis Investigative Site | Miami | Florida | 33126 | — |
| Novartis Investigative Site | Miami | Florida | 33175 | — |
| Novartis Investigative Site | Berlin | New Jersey | 08009 | — |
| Novartis Investigative Site | Duncansville | Pennsylvania | 16635 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Osteopenia trials
Other public records listing Osteopenia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07763509: Calcium-Rich Food Versus Calcium Carbonate for Bone Health Not yet recruiting
- NCT07083557: Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) Recruiting
- NCT07473713: Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia Recruiting
- NCT05283148: Sickle Cell Disease (SCD) Bone Pain Study Active, not recruiting
- NCT04233112: Melatonin and Osteogenic Loading on Osteopenia Active, not recruiting
- NCT05701254: Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01406548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2022 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01406548 live on ClinicalTrials.gov.